Abstract:Introduction: Data on the role of irisin in vascular calcification in patients with end-stage renal diseases on regular dialysis are inconsistent, and the underlying mechanisms are not clearly defined. The present study was designed to explore the association of serum irisin with vascular stiffness and with the impact of well-established risk factors. Methods: The clinical study enrolled 52 hemodialysis (HD) and 15 continuous ambulatory peritoneal dialysis (PD) patients with an age of #x3e;18 years receiving dialysis therapy for #x3e;3 months. Patients who had major pathologies affecting carbohydrate, lipid, and bone metabolism and those who had acute cardiovascular events were excluded. Thirty-seven healthy subjects matched for age and sex served as controls. Routine biochemical parameters were measured in fasting serum samples by standard methods. Serum irisin was determined using the commercial ELISA kit (BioVendor Laboratory Medicine Inc., Brno, Czech Republic). Arterial stiffness parameters – carotid-femoral pulse wave velocity (cf PWV) and augmentation index (Aix) – were measured using applanation tonometry (SphygmoCor System; AtCor Medical, Sydney, Australia). Body composition was assessed by segmental bioelectric impedance (InBody 2.0; Biospace Co. Ltd., Seoul, Korea). Results: It was demonstrated that serum irisin levels were markedly depressed ( p #x3c; 0.05), while the cf PWV significantly increased ( p #x3c; 0.05) in HD/PD patients as compared to controls. Serum irisin proved to be independent of serum insulin, glucose, and HOMA-IR. However, it was inversely related to HbA1c (β = −0.544, p = 0.035), iPTH (β = −0.260, p = 0.035), and alkaline phosphatase ( r = −0.325, p = 0.007). Furthermore, significant negative relationships were found of irisin to serum triglyceride and indices of body fat mass. Retrospective analysis at a follow-up period of 40 months revealed a direct relationship of irisin to all-cause mortality ( p = 0.039). Conclusions: Our study demonstrated that serum irisin levels are reduced in uremic patients on regular HD/PD but failed to establish significant associations of irisin deficiency with vascular stiffness. However, the significant negative relationship of irisin to HbA1c, iPTH, and alkaline phosphatase suggests that it improves insulin sensitivity, inhibits bone resorption, mitigates bone-vascular interaction, and protects vascular function. Blood Purif

Irisin and atherogenic index of plasma novel markers in diabetic patients with and without metabolic syndrome

Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus

The Potential Relationship Between Serum Irisin Concentration With Inflammatory Cytokines, Oxidative Stress Biomarkers, Glycemic Indices and Lipid Profiles in Obese Patients With Type 2 Diabetes Mellitus: A Pilot Study

Circulating Irisin Levels Are Associated with Lipid and Uric Acid Metabolism in a Chinese Population.

Are circulating levels of the myokine irisin linked to type 2 diabetes? A systematic review and meta-analysis

Irisin and Testosterone in Men with Metabolic Syndrome

Irisin Levels Are Associated with Urotensin II Levels in Diabetic Patients.

Association of serum irisin with metabolic syndrome in obese Chinese adults.

Circulating Irisin Level As a Biomarker for Pure Aortic Stenosis and Aortic Valve Calcification

Serum irisin levels in newly diagnosed type-II diabetic patients: No association with the overall diet quality but strong association with fruit intake

Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors

Serum Irisin Level and Its Correlation with Insulin Resistance in Patients with Type 2 Diabetes

Lower Irisin Level in Patients with Type 2 Diabetes Mellitus: A Case‐control Study and Meta‐analysis

Effects of a Combined Endurance/Strength Training Program on Circulating Irisin Levels in Overweight/Obese Men and Women with Type 2 Diabetes Mellitus

Assessment of epicardial adipose tissue and carotid/femoral intima media thickness in insulin resistance

Cardiometabolic Effects of Irisin in Patients with End-Stage Renal Disease on Regular Hemo- or Peritoneal Dialysis

Association of Circulating Irisin Levels and the Characteristics and Prognosis of Coronary Artery Disease.

The Association between the Atherogenic Index of Plasma and Cardiometabolic Risk Factors: A Review

Elevated Circulating Levels of Irisin and the Effect of Metformin Treatment in Women with Polycystic Ovary Syndrome.

Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)